

PSJ17 Exh 41

Actiq® Marketing 2002

Sales Training
March 2002
Christine Wells, APM

Actiq®
(oral transmucosal fentanyl citrate)

Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER


Confidential

CEPHEDPA-AP-01581387
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190736

TEVA_MDL_A_05734046

Overview



- Where have we been?
 - Sales, TRx, Brand Concept
- Where are we now?
 - Sales, TRx, Brand Concept
- 2001 Performance Update
- Why ACTIQ in 2002?
 - Differentiating Benefits / Positioning / Key Messages
- 2002 Key Marketing Issues
- Campaign Tracking Study Results
- Selected Tactics



Produced Pursuant to Confidentiality Agreement



Where have we been?



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER


Confidential

CEPHEDPA-AP-01581389
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190738

TEVA_MDL_A_05734048

Actiq®
(oral transmucosal
fentanyl citrate)

History of ACTIQ



It is important to understand the history of ACTIQ to be able to create a comfort level with your physicians regarding product use and company support

Actiq®
(oral transmucosal fentanyl citrate)

Produced Pursuant to Confidentiality Agreement

CEPHEDPA-AP-01581390
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190739


CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

TEVA_MDL_A_05734049

Confidential

Prior to 2001 Cephalon Relaunch

- **Product Ownership Changes**
 - Lack of continuity – company support??
 - Negative product perception
- **Weak Concepts and Poor Product Positioning**
 - Concepts focused on OT delivery system and clinical entity of BTCP
 - Did not position product based on differentiating benefits
- **BTP Misunderstood**
 - Newer concept – not well understood, assessed, treated by many in pain community




Produced Pursuant to Confidentiality Agreement



2001 Major Challenges

Do you get a second chance to make a first impression?


- Re-concept and reposition product after 2 years of minimal/poor support
- Refocus targeting efforts
- Improve product awareness and perception of ACTIQ's clear, differentiating benefits
- Increase awareness of BTP among prescribers and patients: proper assessment and treatment



Produced Pursuant to Confidentiality Agreement

Actiq®
(oral transmucosal fentanyl citrate)

Where have we been?



NOW AVAILABLE A DELIVERY SYSTEM DESIGNED TO MAKE A DIFFERENCE



■ 1999	• TRx	5,548	\$3.5 MM
	• Gross Sales	20	
	• # of Reps		
■ 2000	• TRx	26,259	\$16.0 MM
	• Gross Sales		
	• # of Reps		

Important Warnings

- Only for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
- Because life-threatening hypoxia could occur at any dose in patients not taking chronic opiates, Actiq is contraindicated in the management of acute or postoperative pain.
- This product must not be used in opioid non-tolerant patients.
- Instruct patients/caregivers: Actiq can be fatal to a child. Keep open units from children and discard properly.
- See boxed warning and full prescribing information on following pages.



Actiq®
(oral transmucosal
fentanyl citrate)

Actiq®
Aptek
Aptek Pharmaceuticals, Inc.
14000 Abbott Rd., Suite 100
Aliso Viejo, CA 92656-5114
1-800-ACTIQ-115



Produced Pursuant to Confidentiality Agreement

Where are we now?



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581394
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190743

TEVA_MDL_A_05734053

Actiq®
(oral transmucosal fentanyl citrate)

Where are we now?


■ 2001

- TRx 73,514
- Gross Sales \$55.0 MM
- # of Reps 48

■ 2002

- TRx 148K+
- Gross Sales \$109 MM
- # of Reps 60

Actiq® on call.



Actiq®
(oral transmucosal
fentanyl citrate)

Produced Pursuant to Confidentiality Agreement


CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

CEPHEDPA-AP-01581395
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190744

TEVA_MDL_A_05734054

Confidential

Year-to-Year Growth Sales, TRx & % Increase



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER


Confidential

CEPHEDPA-AP-01581396
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190745

TEVA_MDL_A_05734055

Actiq®
(oral transmucosal
fentanyl citrate)

2007 Performance Update



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581397
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190746


TEVA_MDL_A_05734056

Actiq®
(oral transmucosal
fentanyl citrate)



4 Key Business Drivers

- # of Prescribers
- # of TRx
- Units/Rx
- Dosage Strength of Rx



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER


Confidential

CEPHEDPA-AP-01581398
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190747

TEVA_MDL_A_05734057

Actiq®
(oral transmucosal fentanyl citrate)

Monthly Prescriber Count Trend and Post-Launch



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER



Confidential

CEPHEDPA-AP-01581399
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190748

TEVA_MDL_A_05734058

Actiq®
(oral transmucosal fentanyl citrate)

Monthly TRx Trend Pre- and Post-Launch



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential


CEPHEDPA-AP-01581400
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190749

TEVA_MDL_A_05734059

Actiq®
(oral transmucosal fentanyl citrate)

© Cephalon, Inc.

Monthly Units and Units/Rx



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER


CEPHEDPA-AP-01581401
 Confidential Treatment Requested by Cephalon, Inc.
 CEP TPP EDPA10190750

Actiq®
 (oral transmucosal fentanyl citrate)

TEVA_MDL_A_05734060

Confidential

Monthly Gross Sales Trend and Post-Launch



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581402
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190751


TEVA_MDL_A_05734061

Actiq®
(oral transmucosal fentanyl citrate)


© Cephalon, Inc.

Prescriber Base by Specialty January 2001 vs. December 2001

January 2001



December 2001



Actiq®
(oral transmucosal fentanyl citrate)

Produced Pursuant to Confidentiality Agreement

CEPHEDPA-AP-01581403
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190752

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER


TEVA_MDL_A_05734062

Confidential

Monthly Prescriber Count by Specialty

Impact of Focused Targeting

- Tremendous growth in Anes/Pain
- Growth in every specialty!



Actiq®
(oral transmucosal fentanyl citrate)

Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER


Confidential

CEPHEDPA-AP-01581404
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190753

TEVA_MDL_A_05734063

TRx Trend by Specialty

Impact of Focused Targeting



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER


Confidential

CEPHEDPA-AP-01581405
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190754

TEVA_MDL_A_05734064

Actiq®
(oral transmucosal fentanyl citrate)

Average TRx/Prescriber by Specialty 2000 vs. 2000



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581406
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190755


TEVA_MDL_A_05734065

Actiq®
(oral transmucosal fentanyl citrate)

TRX Trend by Strength

Impact of Titration Messaging

- 200 & 800mcg TRx growing at fastest rate
- Titration messaging has been effective



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

CEPHEDPA-AP-01581407
 Confidential Treatment Requested by Cephalon, Inc.
 CEP TPP EDPA10190756


TEVA_MDL_A_05734066

Actiq®
 (oral transmucosal fentanyl citrate)

© Cephalon, Inc.

Confidential

Two Consultant Meetings San Diego Meetings – 2001



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581408
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190757


TEVA_MDL_A_05734067

Actiq®
(oral transmucosal fentanyl citrate)

2001 Performance Update Summary

Four Key Business Drivers

- Prescriber Count
 - Average month-to-month growth since relaunch: 17%
- Total Prescriptions
 - Average month-to-month growth since relaunch: 23%
- Total Units
 - Average month-to-month growth since relaunch: 10%
 - Units/Rx no longer in decline and above 50 units/Rx
- TRx Strength
 - 400 & 800 growing at fastest rate
- Gross Factory Sales
 - Average month-to-month growth since relaunch: 23%
 - 244% growth over 2000 (\$55.0 MM vs. \$16.0 MM)



Produced Pursuant to Confidentiality Agreement




Prescriber Productivity Summary

Full Year 2001

Specialty	% of Prescriber Base	% of TRx	% of Sales
FG	10%	7%	10%
IM	11%	8%	6%
Neuro	6%	7%	6%
Oncology	19%	11%	7%
Other	18%	12%	8%
Anes/Pain	35%	55%	62%

Specialty	Avg TRx/Prescriber	Avg Units/TRx
FG	9.4	65.9
IM	8.3	50.8
Neuro	25.5	50.7
Oncology	7.3	38.0
Other	8.4	45.4
Anes/Pain	33.7	57.6



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581410
 Confidential Treatment Requested by Cephalon, Inc.
 CEP TPP EDPA10190759

TEVA_MDL_A_05734069

Actiq®
 (oral transmucosal fentanyl citrate)



Why have we been successful?

- Targeting correct physician specialties
- Delivering ACTIQ's key messages (benefits of rapid onset)
- Implementing appropriate and effective medical education programs
 - ❖ Sales-driven MEPS
 - ❖ Consultant meetings
 - ❖ CME programs; newsletter, website, teletopics, symposia
- Educating key physician targets
 - ❖ Titration process
 - ❖ Relative potency of ACTIQ
 - ❖ Patient selection
- Improving product awareness
 - ❖ Media plan (journal ads)
 - ❖ Convention presence
 - ❖ Direct mailings (medical & promotional)

Actiq®
(oral transmucosal fentanyl citrate)

Produced Pursuant to Confidentiality Agreement


CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581411
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190760

TEVA_MDL_A_05734070

What ACTIQ in 2002... and beyond?



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential


CEPHEDPA-AP-01581412
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190761

TEVA_MDL_A_05734071

Actiq®
(oral transmucosal
fentanyl citrate)

Differentiation of ACTIQ

- Why ACTIQ and not another short-acting opioid?
- ACTIQ's key differentiating benefit meets a critical unmet need
- * Rapid onset of analgesia
 - Critical feature in treating BTP and episodic pain



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581413
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190762


TEVA_MDL_A_05734072

Actiq®
(oral transmucosal fentanyl citrate)



2002 ACTIQ Positioning

- ACTIQ is
 - * a medication in a unique oral transmucosal delivery system
 - * that provides the most rapid onset of analgesia of any non-invasive opioid formulation available
 - * and affords patients personal pain control for BTP and episodic pain



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581414
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190763

TEVA_MDL_A_05734073

Actiq®
(oral transmucosal)
fentanyl citrate



2002 ACTIQ Key Messages

Messages may appear differently in promotional materials

■ ACTIQ

- Provides rapid onset of analgesia*
- Provides personal pain control by improving functionality and QoL*
- Has a unique, revolutionary drug delivery system
- Is most effective when titration is initiated at 400mcg
- Is safe and highly effective*
- Is easy and convenient to use*
- Is the only product specifically indicated for BTCP
- * Characteristics of ACTIQ which rated extremely high in market research “satisfaction ratings”

Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581415
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190764

TEVA_MDL_A_05734074

Actiq®
(oral transmucosal fentanyl citrate)

© Cephalon, Inc.

2002 Key Marketing Issues

2002

Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential


CEPHEDPA-AP-01581416
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190765

TEVA_MDL_A_05734075

Actiq®
(oral transmucosal
fentanyl citrate)

2002 Key Marketing Issues

1. Low product awareness among targeted physician specialties (especially “awareness” linked to key benefits)
2. Lack of knowledge in the assessment and treatment of BTP and episodic pain among targeted physician specialties
3. Limited clinical data and publications outside of cancer patient population and supporting simplified titration
4. Low product and disease state awareness among pain patients
5. Limited direct promotional reach



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581417
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190766

TEVA_MDL_A_05734076

Actiq®
(oral transmucosal fentanyl citrate)


© Cephalon, Inc.

The Big Questions

How will we:

- Address these key issues
- Deliver ACTIQ's key messages
- Effectively position the product in 2002?

- Continue to utilize current brand concept
- Establish appropriate strategies
 - * No real change in direction
- Execute effective tactics
 - * We will review shortly



Produced Pursuant to Confidentiality Agreement



Positioning Conveyed Through Brand Concept



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER



Confidential

CEPHEDPA-AP-01581419
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190768

TEVA_MDL_A_05734078

Actiq®
(oral transmucosal fentanyl citrate)

Strategically Addressing Key Issues




Produced Pursuant to Confidentiality Agreement

Actiq®
(oral transmucosal fentanyl citrate)

CEPHEDPA-AP-01581420
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190769

TEVA_MDL_A_05734079

2002 Selected Tactics



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581421
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190770


TEVA_MDL_A_05734080

Actiq®
(oral transmucosal fentanyl citrate)



2002 Selected Tactics

- Consultant Meetings
- CME / CE
- Promotional Materials



Produced Pursuant to Confidentiality Agreement

Actiq®
(oral transmucosal fentanyl citrate)

Consultants Meetings

- March 22-24 Ft. Lauderdale, FL
- June 21-23 San Diego, CA
- October 25-27 Dallas, TX

- Targeting 60 physicians at each meeting
- Objectives
- Drive scripts
- Identify speakers / champions

Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581423
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190772

TEVA_MDL_A_05734082


Actiq®
(oral transmucosal fentanyl citrate)



CME / CE

■ Five Key Initiatives

- 3 programs extended from 2001
- Newsletter: Emerging Solutions in Pain
- Symposia
- Website: *EmergingSolutionsinPain.com*
- 2 new programs
- Breakthrough Pain Category on *Pain.com*
- Teleconferences




Produced Pursuant to Confidentiality Agreement



CME / CE – Extended Programs

1. Newsletter

- 1st Newsletter mailed November 2001
- 2002 – Trimesterly
 - February, June & October
 - Will allow for varied topics and create a credible CME resource
- Circulation of 10K (80% MDs)
 - BRCs mailed to original mailing list
 - Reps will be provided with BRCs
 - Clinicians / Reps can sign up at website



Produced Pursuant to Confidentiality Agreement



CME Newsletter

Emerging Solutions in Pain

www.EmergingSolutionsinPain.com

Spring 2002
Volume II
Number 1

*An educational resource
for clinicians in the field
of pain management*

Published by:
 MediCom
Worldwide, Inc.

Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581426
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190775

TEVA_MDL_A_05734085

The Clinical Expert

www.EmergingSolutionsinPain.com

*An independent study CD-ROM program presented
by Dr. Steven P. Positto addressing
substance abuse issues and chronic pain*


For additional continuing education opportunities, please visit us at:
www.EmergingSolutionsinPain.com

MediCom gratefully acknowledges the receipt of an educational grant in support of this publication from Cephalon, Inc.

Cephalon

©2002, MediCom Worldwide, Inc.
101 Washington St., Monroeville, PA 15067
No portion of this material may be copied or duplicated without the expressed permission of MediCom.

Business Reply Card



To continue receiving your complimentary subscription to *Emerging Solutions in Pain*, please fill out this form and return it to MedNet.com Worldwide, Inc. via mail, fax (215-535-0900) or online at www.EmergingSolutionsinPain.com

Free subscriptions are available only to those who hold one of the positions in Pain Management listed below. If you do not qualify, paid subscriptions are available and can be ordered by calling 800-408-4242. Thank you!

A subscription offer for
updates and continuing
education

Yes! I want to receive complimentary quarterly
publications of *Emerging Solutions in Pain*
 No thank you.

Specialty: Please check which best describes your
position and/or specialty.


Pain Management	Obstetrics	Emergency Medicine
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anesthesiology	Neurology	Orthopedics
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Internal Medicine	Psychiatry	Urology
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Primary Care	Podiatry	Other
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
MD	DO	NP
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
RN	CNA	Other
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Name _____
Title _____
Institution: _____
Department: _____
Address: _____
City/State: _____
Postal/Zip Code: _____ County: _____
Telephone: _____ Fax: _____
Email Address: _____
Signature: _____ Date: _____

CME / CE – Extended Programs

2. Symposia

- Different strategy than in 2001
 - 25 cities with target of 20-30 MDs per program
 - Fewer presenters / topics
 - ❖ BTP & Abuse, Addiction, Diversion
 - Expanded reach with concentrated effort
 - Major rep involvement with physician recruitment
- Timing: February through November 2002



Produced Pursuant to Confidentiality Agreement



Symposia Invitation



New Challenges in the Effective Management of Chronic Pain
Just a reminder...

A complimentary dinner will accompany the educational activity.

This educational symposium will review the new and evolving guidelines on pain management, as well as focus on two key components associated with ongoing pain management: recognition that even patients with effective analgesic regimens will still experience occasional breakthrough pain and the clinical concerns related to potential and real substance abuse issues.

CME CREDIT

Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education. MediCom Worldwide, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement: MediCom Worldwide, Inc. designates this educational activity for up to 1.5 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent completing the educational activity.

Date _____

Program Time _____

Location _____

Supported by an educational grant from Cephalon, Inc.

Cephalon

To register for this program, please call **800-408-4242, ext. 33.**

Produced Pursuant to Confidentiality Agreement

CEPHEDPA-AP-01581429

Confidential Treatment Requested by Cephalon, Inc.

CEP TPP EDPA10190778

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER


TEVA_MDL_A_05734088

Confidential

CME / CE – Extended Programs

3. EmergingSolutionsinPain.com

- Launched August 2001
- Repository of all programs
 - Creates enduring materials for rep referral
 - Registration for newsletter / future programs



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential


CEPHEDPA-AP-01581430
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190779

TEVA_MDL_A_05734089

Actiq®
(oral transmucosal fentanyl citrate)

© Cephalon, Inc.

CME Website: *EmergingSolutionsinPain.com*



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581431
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190780

TEVA_MDL_A_05734090

CME / CE – New Programs

1. Breakthrough Pain Category on *Pain.com*
 - Most popular “pain” website (200K hits/month)
 - ❖ Dannemiller Memorial Educational Foundation
 - Cephalon is sole sponsor of “Breakthrough Pain” category
 - ❖ Unique URL: *Pain.com/breakthroughpain*
 - Initial core offerings include:
 - ❖ CME/CE module on BTP (10 studies abstracted)
 - ❖ Expert interviews (with site editor and guest MD)
 - ❖ Selected articles on BTP
 - ❖ Case histories
 - ❖ Patient education and information resources
 - ❖ Ask the Pain Doctor
 - ❖ FAQs
 - Additional CME offerings / updates every 3 to 6 months
 - Targeted Launch: Q3 2002

Produced Pursuant to Confidentiality Agreement






CME / CE – New Programs

2. Teleconferences

- Pilot program – only 6 in 2002
- Topic: Treatment Advances in CRPS
- Timing: June – Aug 2002
- Targeting 20-30 MDs/call
- If successful, additional dates possible



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER



Confidential

CEPHEDPA-AP-01581433
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190782

TEVA_MDL_A_05734092

Aqtiq®
(oral transmucosal fentanyl citrate)

Proprietary Materials Update



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581434
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190783


TEVA_MDL_A_05734093

Actiq®
(oral transmucosal
fentanyl citrate)

2001 Core Promotional Materials

Available Now:

- 2001 Sales Aid
- Patient FAQs
- Physician FAQs
- Dosing Guide (old concept)
- Product Monograph
- Reimbursement Brochure
- Pain Assessment Tear Sheet (non-branded)
- 3 Non-ACTIQ Specific Reprints



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581435
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190784

TEVA_MDL_A_05734094


Actiq®
(oral transmucosal fentanyl citrate)



2002 Additions

Available Soon:

- 5 ACTIQ-specific Reprints
- Non-branded BTP Wall Chart
- New “Pocket-Size” Dosing Guide
- New PCS Coupons (with dosing instructions)
- Patient Instructional Use Tear Sheet
- 2001 Sales Aid – Revised
- Medi-Message Pads
- New Magnet & Rolodex Card
- ACTIQ.com



Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581436
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190785

TEVA_MDL_A_05734095

Actiq®
(oral transmucosal fentanyl citrate)



2002 Additions

Other Possibilities:

- Competitive Comparison PK Sales Aid
- Patient Profile Flash Cards
- Formulary Kit
- Promotional Direct Mailings

Giveaways:

- 3 Different Style Pens
- Travel Coffee Mugs
- Medi-Message Pads
- And last but not least...

Produced Pursuant to Confidentiality Agreement

CONFIDENTIAL PER STIPULATION AND PROTECTIVE ORDER

Confidential

CEPHEDPA-AP-01581437
Confidential Treatment Requested by Cephalon, Inc.
CEP TPP EDPA10190786

TEVA_MDL_A_05734096


Actiq®
(oral transmucosal fentanyl citrate)



Critical Success Factors for 2002

Marketing & Sales

- Creation of key sales aids/promotional pieces
- Modification of Brand Concept
- Implementation of Public Relations Plan
- PCS-driven MEPs
- CME Programs
- Consultant Meetings



Produced Pursuant to Confidentiality Agreement

Actiq®
(oral transmucosal fentanyl citrate)